Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up

Overview of attention for article published in JAMA Ophthalmology, April 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#34 of 4,526)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 84 news outlets
blogs: 1 blog

twitter: 13 X users
patent: 2 patents

Readers on

mendeley: 102 Mendeley

So far, Altmetric has seen 108 news stories from 84 outlets.

Physician perspective: Glaucoma eye drops are here to stay

Ophthalmology Times Europe, 10 Apr 2026

Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.

Physician perspective: Glaucoma eye drops are here to stay

Ophthalmology Times, 12 Feb 2026

For as long as I can recall, there has been ongoing discussion about the drawbacks of initiating glaucoma therapy with IOP–loweri…

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

AP News, 26 Sep 2023

IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free formulation of latanoprost, the most…

Thea Pharma Inc. Launches IYUZEH™ (latanoprost ophthalmic solution) 0.005% in the U.S.

ProfitQuotes.com, 26 Sep 2023

IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free formulation of latanoprost, the most…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 104 additional news stories.